← Research library

Cerebrolysin in first-degree relatives: cognitive follow-up by ApoE genotype

Observational study · 2020

What was studied
72 first-degree relatives. Forty-six had mild cognitive difficulties and 26 met diagnostic criteria for mild cognitive impairment.
Main finding
In 72 treated relatives, the authors reported weaker immediate and follow-up cognitive changes in ApoE4 carriers than in noncarriers.

Reported findings and study design

Findings described in words

Repeated cognitive assessments by baseline severity and ApoE4 genotype.

Population or model 72 first-degree relatives. Forty-six had mild cognitive difficulties and 26 met diagnostic criteria for mild cognitive impairment.

Dose, route and schedule

A four-week intravenous infusion course. Assessments immediately after the course and at one and two months later. The checked abstract does not give the infusion volume.

Protocol source ↗ · Original indexed abstract, subgroup denominators and assessment schedule.

Results · Original indexed abstract, subgroup denominators and assessment schedule.
MeasureResultComparison, timing and statistics
Cognitive outcomes by ApoE4 genotypeThe authors report smaller immediate and delayed changes in ApoE4 carriers.End of course and one- and two-month follow-up

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • All participants received treatment. The abstract provides no genotype subgroup sizes or effect estimates. Overlap with other reports from the same center remains unverified.

Related publications may describe some of the same participants or experiments.

Source details

Original indexed abstract, subgroup denominators and assessment schedule.

Sources checked

Citation

Uncontrolled human reportEnglish abstract

N. D. Selezneva, S. I. Gavrilova, I. V. Kolykhalov. Cerebrolysin in first-degree relatives: cognitive follow-up by ApoE genotype Korsakov Journal of Neurology and Psychiatry. 2020;120(10 Suppl 2):31–38.

Study source ↗ · DOI 10.17116/jnevro202012010231 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards